Neuronetics Q4 GAAP EPS $(0.19) Beats $(0.26) Estimate, Sales $20.31M Beat $19.85M Estimate
Portfolio Pulse from Benzinga Newsdesk
Neuronetics (NASDAQ:STIM) reported Q4 GAAP EPS of $(0.19), surpassing the $(0.26) estimate, and sales of $20.31M, exceeding the $19.85M estimate. This represents a 36.67% increase in EPS and an 11.63% increase in sales from the same period last year.
March 05, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neuronetics reported a significant beat on both EPS and sales estimates for Q4, indicating strong financial performance and growth.
Beating both EPS and sales estimates by a notable margin suggests operational efficiency and market demand for Neuronetics' offerings. This positive earnings report is likely to instill investor confidence and could lead to a short-term uptick in STIM's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100